Labat Africa (JSE:LAB) EPS without NRI: R0.11 (TTM As of Nov. 2025)


What is Labat Africa EPS without NRI?

Labat Africa JSE:LAB EPS without NRI is R0.11 as of Nov. 2025. The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, Labat Africa ranks better than 77.1% on this metric.

Labat Africa's earnings per share without non-recurring items for the six months ended in Nov. 2025 was R0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2025 was R0.11.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 31.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Labat Africa's EPS without NRI or its related term are showing as below:

JSE:LAB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.4   Med: -13.9   Max: 31.2
Current: 31.2

During the past 13 years, Labat Africa's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 31.20% per year. The lowest was -58.40% per year. And the median was -13.90% per year.

JSE:LAB's 3-Year EPS without NRI Growth Rate is ranked better than
77.1% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs JSE:LAB: 31.20

Labat Africa's EPS (Diluted) for the six months ended in Nov. 2025 was R0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 was R0.13.

Labat Africa's EPS (Basic) for the six months ended in Nov. 2025 was R0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2025 was R0.13.


Labat Africa  (JSE:LAB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Labat Africa EPS without NRI Related Terms


Labat Africa EPS without NRI Historical Data

* Premium members only.

The historical data trend for Labat Africa's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labat Africa EPS without NRI Chart

Labat Africa Annual Data
Trend Feb14 Feb15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 May23 May24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.12 -0.06 -0.07 -0.04

Labat Africa Semi-Annual Data
Aug15 Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.05 0.01 0.07 0.04

JSE:LAB vs ZTS, UTHR, VTRS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labat Africa PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labat Africa's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Labat Africa's PE Ratio without NRI falls into.



Labat Africa EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Nov. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of R0.11 mean?
Labat Africa (JSE:LAB) has a EPS without NRI of R0.11 as of Nov. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #180 out of 786 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Labat Africa's EPS without NRI too high?
Labat Africa's current EPS without NRI is R0.11. Based on the distribution chart, Labat Africa ranks #180 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #180 out of 786 companies for EPS without NRI. This places Labat Africa in the top 23% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current EPS without NRI is R0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.05 — trading 77.3% below its estimated fair value. The current EPS without NRI is R0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current EPS without NRI is R0.11 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.